Hyperfine (HYPR) AI Stock Analysis

• Market Cap: $120.49M
• Dividend Yield: N/A
• Average Volume (3M): 762.74K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.04
• Revenue Growth: -20.10%
• EPS Growth: 7.87%
• Country: US
• Employees: 111
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.14
• Shares Outstanding: 82,113,370
• 10 Day Avg. Volume: 1,646,855
• 30 Day Avg. Volume: 762,741
• PEG Ratio: 0.16
• Price to Book (P/B): 1.30
• Price to Sales (P/S): 4.94
• P/FCF Ratio: -1.63
• Enterprise Value/Market Cap: 0.26
• Enterprise Value/Revenue: 2.91
• Enterprise Value/Gross Profit: 6.32
• Enterprise Value/Ebitda: -0.76
• 1Y Price Target: $2.00
• Price Target Upside: 102.02% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: $1.00 ▲(1.01% Upside)

HYPR scores held back primarily by weak financial performance (volatile/declining TTM revenue, large operating losses, and ongoing cash burn despite low debt). Offsetting this, the earnings call was positive on momentum (sequential revenue growth, record gross margin, improved cash burn, and extended runway). Technicals and valuation remain neutral-to-weak, providing limited additional support.

Positive Factors

Revenue Growth

The sequential revenue growth indicates strong demand and market acceptance of Hyperfine's products, supporting long-term business expansion.

Product Innovation

The successful launch of new products enhances Hyperfine's competitive edge and positions it for future growth in the medical imaging market.

Cash Position

A strong cash position ensures financial stability and supports ongoing R&D and market expansion efforts, crucial for long-term sustainability.

Negative Factors

Profitability Challenges

Persistent net losses highlight ongoing profitability challenges, which could hinder long-term financial health and operational efficiency.

High Operating Expenses

High operating expenses reflect significant investment needs, which may pressure margins and delay profitability, impacting long-term viability.

Negative Cash Flow

Continuous negative cash flow poses a risk to sustainability, limiting the company's ability to invest in growth and manage financial obligations.

Hyperfine Business Overview & Revenue Model

Company Description

Hyperfine, Inc. provides imaging, monitoring, and magnetic resonance imaging products. It offers Swoop Portable MR imaging system to address an unmet need in point-of-care medical imaging through a combination of hardware and software services. The company was incorporated in 2014 and is based in Guilford, Connecticut.

How the Company Makes Money

Hyperfine generates revenue through the sale and leasing of its Swoop Portable MRI systems to hospitals, clinics, and healthcare providers. The company also earns income from the provision of maintenance, support services, and software updates for its imaging systems. Additionally, Hyperfine has established partnerships with healthcare institutions and organizations that contribute to its credibility and market reach, as well as collaborations that may yield further revenue opportunities through research and development initiatives.

Hyperfine Financial Statement Overview

Summary

Hyperfine shows strong revenue growth and a solid equity position with no debt. However, significant profitability challenges persist, with continuous net losses and negative cash flows. The high equity ratio and lack of debt provide stability, but negative ROE and cash flow issues indicate a need for improved operational efficiency and profitability.

Income Statement

Hyperfine's income statement shows significant revenue growth over the years, with the latest revenue of $12.89 million compared to $0.29 million in 2020. However, the company continues to operate at a loss, with a net loss of $40.72 million for 2024. The gross profit margin has improved to 45.7% in 2024 from a negative margin in earlier years, but net profit margins remain substantially negative. The EBIT and EBITDA margins are also deeply negative, indicating ongoing operational challenges. The revenue growth is a positive sign, but the persistent losses are a major concern.

Balance Sheet

The balance sheet of Hyperfine shows a relatively strong equity position with stockholders' equity at $49.04 million by the end of 2024. The company has no debt, resulting in a debt-to-equity ratio of 0, which is a positive aspect. However, the return on equity is negative due to significant net losses. The equity ratio stands at 83.2%, indicating a strong capital structure. The absence of debt and a high equity ratio are strengths, yet the negative ROE reflects profitability challenges.

Cash Flow

Hyperfine's cash flow statement reveals negative free cash flow, with a free cash flow of -$39.15 million in 2024. Operating cash flow exceeds net income, suggesting decent cash conversion efficiency, but both metrics are negative. The company has been investing less over time, which may impact future growth prospects. While the company has managed to finance operations without debt, the continuous negative cash flows pose a risk to long-term sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.59M	12.89M	11.03M	6.81M	1.50M	294.00K
Gross Profit	4.88M	5.89M	4.76M	907.00K	-1.17M	-477.00K
EBITDA	-40.87M	-42.22M	-47.06M	-72.86M	-64.14M	-23.20M
Net Income	-40.05M	-40.72M	-44.24M	-73.16M	-64.83M	-23.36M
Balance Sheet
Total Assets	41.51M	58.90M	94.20M	134.05M	202.47M	71.53M
Cash, Cash Equivalents and Short-Term Investments	21.56M	37.65M	75.18M	118.24M	188.50M	62.68M
Total Debt	0.00	269.00K	185.00K	0.00	0.00	178.00K
Total Liabilities	14.64M	9.86M	9.80M	10.33M	16.25M	4.29M
Stockholders Equity	26.87M	49.04M	84.40M	123.72M	186.23M	67.23M
Cash Flow
Free Cash Flow	-32.23M	-39.15M	-42.61M	-72.92M	-49.89M	-23.09M
Operating Cash Flow	-31.10M	-38.77M	-41.81M	-72.34M	-47.18M	-21.52M
Investing Cash Flow	-1.13M	-383.00K	-804.00K	-585.00K	-2.71M	-1.57M
Financing Cash Flow	8.27M	1.02M	174.00K	7.00K	176.77M	60.94M

Hyperfine Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.99
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYPR, the sentiment is Positive. The current price of 0.99 is below the 20-day moving average (MA) of 1.03, below the 50-day MA of 1.04, and below the 200-day MA of 1.03, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 66.72 is Neutral, neither overbought nor oversold. The STOCH value of 88.26 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HYPR.

Hyperfine Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FONR	66 Neutral	$117.43M	16.82	4.34%	―	3.36%	-21.15%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HYPR	50 Neutral	$120.49M	-2.37	-94.03%	―	-20.10%	7.87%
VVOS	46 Neutral	$18.79M	-1.06	-335.47%	―	18.76%	60.09%
RBOT	45 Neutral	$20.07M	-0.31	-148.93%	―	―	15.03%
ICCM	45 Neutral	$46.62M	-2.65	-157.91%	―	-18.96%	8.98%

Hyperfine Corporate Events

Hyperfine Announces Strong Preliminary Q4 2025 Revenue Growth

On January 12, 2026, Hyperfine reported preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025, highlighting a record fourth-quarter revenue of about $5.3 million, up 127% year-on-year and 54% sequentially, driven by placements across hospital, neurology office and international markets. For full-year 2025, revenue is expected to reach approximately $13.5 million, a modest 5% increase over 2024, while preliminary net cash burn excluding financings improved, declining 30% year-on-year in the fourth quarter to about $5.7 million and 22% for the full year to about $29.9 million, leaving the company with an estimated $35.1 million in cash and cash equivalents at year-end; these trends suggest strengthening commercial traction for its next-generation Swoop® system and Optive AI™ software alongside tighter cash management, though figures remain subject to final audit and a full earnings release expected in March 2026.

The most recent analyst rating on (HYPR) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Hyperfine stock, see the HYPR Stock Forecast page.

Hyperfine Expands ATM Equity Offering With New Sales Agent

On December 29, 2025, Hyperfine, Inc. amended and restated its existing at-the-market equity offering arrangement, expanding its distribution syndicate by adding BTIG, LLC as an additional sales agent alongside B. Riley Securities, Inc., while keeping all other material terms unchanged. Under the revised agreement and a newly filed prospectus supplement tied to its effective shelf registration, the company may, at its discretion, sell up to $50 million of Class A common stock through the agents, who will receive up to a 3% commission, and Hyperfine has simultaneously terminated an earlier prospectus supplement dated November 22, 2023, under which it had previously sold 3,464,325 shares for approximately $4.35 million in gross proceeds.

The most recent analyst rating on (HYPR) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Hyperfine stock, see the HYPR Stock Forecast page.

Hyperfine Announces Underwriting Agreement for Stock Offering

On October 15, 2025, Hyperfine, Inc. entered into an underwriting agreement with Lake Street Capital Markets, LLC, to issue and sell 14,000,000 shares of Class A common stock at $1.25 per share, expecting gross proceeds of approximately $17.5 million. The offering, set to close around October 17, 2025, aims to support Hyperfine’s working capital and general corporate purposes, including commercial, manufacturing, and R&D activities, potentially impacting its operational capabilities and market positioning.

The most recent analyst rating on (HYPR) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Hyperfine stock, see the HYPR Stock Forecast page.

Hyperfine Reports Strong Q3 2025 Revenue Growth

On October 15, 2025, Hyperfine, Inc. announced preliminary, unaudited financial results for the third quarter of 2025, highlighting strong business momentum following the launch of its next-generation Swoop® system. The company reported a 27% sequential revenue growth to approximately $3.4 million and a 36% increase in the average device selling price. The successful commercial rollout of the Swoop® system and Optive AI™ software has led to significant traction in the U.S. hospital pipeline, with new placements across critical care and emergency departments. This expansion signals a promising outlook for Hyperfine’s market positioning and stakeholder interests.

The most recent analyst rating on (HYPR) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Hyperfine stock, see the HYPR Stock Forecast page.